Grove Biopharma Funding: $30M Raised, Series A (2025)
Grove Biopharma is based in Chicago. It has raised $30M in total funding. Latest round: Series A. Backed by DCVC Bio, Eli Lilly and Company, InVivium Capital.
Grove Biopharma funding overview
Grove Biopharma is based in Chicago. Grove Biopharma has raised $30M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in April 2025. The round record for Grove Biopharma runs through 2025; nothing later has been disclosed. Investors on record include DCVC Bio, Eli Lilly and Company, InVivium Capital, Walder Ventures, Gradiant Corporation, Mansueto Investments and 1 others. 7 distinct backers are named across the disclosed rounds.
Grove Biopharma at a glance
Total raised
$30M
Latest round
Series A
Latest round date
April 2025
Headquarters
Chicago
Notable investors
DCVC Bio, Eli Lilly and Company, InVivium Capital, Walder Ventures, Gradiant Corporation, Mansueto Investments, Portal Innovations
Frequently asked about Grove Biopharma funding
How much has Grove Biopharma raised?
Grove Biopharma has raised $30M in total disclosed funding across the rounds on record.
Who has invested in Grove Biopharma?
DCVC Bio, Eli Lilly and Company, InVivium Capital, Walder Ventures, Gradiant Corporation, Mansueto Investments are named among the investors backing Grove Biopharma.
What was the latest Grove Biopharma funding round?
The most recent disclosed round is a Series A, announced in April 2025.
Where is Grove Biopharma based?
Grove Biopharma is based in Chicago.
When did Grove Biopharma last raise?
The last disclosed Grove Biopharma round closed in April 2025 at Series A.
Totals shown for Grove Biopharma aggregate every disclosed round on file. To see how that compares, browse the companies in Chicago and the investors behind them below.
